A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhibitors.
Phase of Trial: Phase III
Latest Information Update: 26 Sep 2013
At a glance
- Drugs Tadalafil (Primary)
- Indications Erectile dysfunction
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 27 Dec 2012 New source identified and integrated (German Clinical Trials Register record: DRKS00004118).
- 01 Sep 2011 Results published in the Journal of Sexual Medicine.
- 15 Dec 2010 Last checked against ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History